24th week of 2012 patent applcation highlights part 41 |
Patent application number | Title | Published |
20120148545 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 2012-06-14 |
20120148546 | PERICYTE PROGENITOR CELLS AND METHODS OF GENERATING AND USING SAME - Provided are methods of isolating pericyte progenitor cells from pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, by isolating CD105+, CD73+ and/or CD105+/CD73+ cells from embryoid bodies and optionally by enriching the cells with CD31− cells. Also provided are methods of isolating endothelial cells and co-derivation of pericyte and endothelial cells progenitor cells from embryoid bodies, and methods of differentiating same for various therapeutic applications. In addition, the invention provides an isolated pericyte progenitor cell having an expression marker signature of CD105+/CD73+CD31−/alpha SMA−/CD133−/Flk-1−. | 2012-06-14 |
20120148547 | COMBINATION OF VITAMIN E AND BETA-GLYCOSPHINGOLIPIDS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HEPATIC DISORDERS - The present invention relates to combined compositions comprising a combination of at least one natural or synthetic beta-glycolipid and at least one tocopherol (vitamin E). The invention further provides methods and kits using said combined compositions for treating and preventing hepatic disorders, specifically, liver insult cause by hepatotoxic drugs or caused by any one of infectious, metabolic, toxic, immune, or perfusion or blood flow related hepatic injury. | 2012-06-14 |
20120148548 | Joint Repair Using Mesenchymal Stem Cells - A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue. | 2012-06-14 |
20120148549 | METHOD TO ISOLATE, IDENTIFY, AND USE EMBRYONIC STEM CELLS DIRECTED TO FOREBRAIN INTERNEURON FATE - The present invention relates to methods of isolating a purified or enriched population of cortical or striatal immature interneuron progenitor cells and the isolated purified or enriched population of immature interneuron progenitor cells. Methods of treating a condition mediated by a loss or deficiency of interneuron function using the purified or enriched population of immature interneuron progenitor cells are also disclosed. | 2012-06-14 |
20120148550 | METHODS, SYSTEMS, AND COMPOSITIONS FOR NEURONAL DIFFERENTIATION OF MULTIPOTENT STROMAL CELLS - Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function. | 2012-06-14 |
20120148551 | MARROW STEM CELL AND PANCREATIC BETA CELL FUSION CELL USEFUL FOR THE TREATMENT OF DIABETES - Methods described include methods of treating T1DM, the method comprising delivering a therapeutic amount of β-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell. | 2012-06-14 |
20120148552 | METHOD AND COMPOSITIONS FOR ENHANCED ANTI-TUMOR EFFECTOR FUNCTIONING OF T CELLS - Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13Rα2 specific IL13-zetakine (IL13ζ), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors. | 2012-06-14 |
20120148553 | METHODS OF GENERATING NATURAL KILLER CELLS - Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection. | 2012-06-14 |
20120148554 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES - Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress. | 2012-06-14 |
20120148555 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided. | 2012-06-14 |
20120148556 | Formulations for Lysosomal Enzymes - The present invention provides improved formulations for lysosomal enzymes useful for enzyme replacement therapy. Among other things, the present invention provides formulations that preserve or enhance the stability and/or efficacy of a lysosomal enzyme such as acid alpha-glucosidase. | 2012-06-14 |
20120148557 | ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS - The present invention relates to pharmaceutical preparations comprising albumin-fused coagulation factors for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders and to a method for increasing the in-vivo recovery after non-intravenous administration of a coagulation factor by fusing it to albumin. | 2012-06-14 |
20120148558 | Delivery of Therapeutic Compounds to the Brain and Other Tissues - The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders. | 2012-06-14 |
20120148559 | COMPOSITIONS AND METHOD FOR DEIMMUNIZATION OF PROTEINS - The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. | 2012-06-14 |
20120148560 | NEUROPROTECTION FROM BRAIN ANOXIA AND REPERFUSION INJURY DURING STROKE AND COMPOSITIONS OF PKG PATHWAY ACTIVATORS AND METHOD OF USE THEREOF - A pharmaceutical composition for treating or preventing one or both of neural anoxia and reperfusion injury, which includes a pharmacological activator of the PKG pathway, and methods of treating or preventing medical conditions using a pharmacological activator of the PKG pathway. | 2012-06-14 |
20120148561 | USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts. | 2012-06-14 |
20120148562 | METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS ASSOCIATED WITH VASCULAR HYPER-REACTIVITY - The present invention provides a methods and compositions for treating a patient having a skin condition characterized by vascular hyper-reactivity, such as chronic or episodic flushing or blushing, and/or rosacea. The method comprises applying a topical composition to affected areas of the patient's skin. The topical composition comprises an effective amount of a botulinum neurotoxin for decreasing vasodilation in cutaneous microvasculature, and a carrier for effectively transporting the botulinum toxin to the cutaneous microvasculature. The invention thereby provides a safe, effective, comfortable, and/or convenient manner of treating vascular hyper-reactivity in skin. | 2012-06-14 |
20120148563 | Method for Treating Premature Ejaculation with a Botulinum Neurotoxin - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 2012-06-14 |
20120148564 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY - Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof. | 2012-06-14 |
20120148565 | INCREASING LIFESPAN BY MODULATION OF WWP-1 AND UBC-18 - Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan in animals. Methods of screening for compounds that modulate longevity by assaying wwp-1 ubiquitination pathway parameters are provided, as are related systems. In addition, methods of using wwp-1 and/or ubc-18 to modulate longevity or delay onset of age-related diseases are described. | 2012-06-14 |
20120148566 | PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION - Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods. | 2012-06-14 |
20120148567 | PARTICULATE HYALURONIC ACID FORMULATIONS FOR CELLULAR DELIVERY OF BIOACTIVE AGENTS - There is presently provided a suspension of immiscible particles in a solution, wherein the particles comprise an agglomeration of a bioactive agent; and a plurality of conjugates of a hyaluronic acid and a flavonoid wherein the particles are on average from about 15 nm to about 300 nm in diameter and wherein the bioactive agent is releasably retained in the particles by the flavonoid. There is also provided a therapeutic formulation comprising such a suspension and methods for using the suspension and therapeutic formulation, including for delivery of a bioactive agent to a cell and for treating a disease, including cancer. | 2012-06-14 |
20120148568 | Variant Immunoglobulins with Improved Manufacturability - This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels. | 2012-06-14 |
20120148569 | PICRORHIZA KURROA EXTRACT FOR PREVENTION, ELIMINATION AND TREATMENT OF INFECTION DISEASES - An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of | 2012-06-14 |
20120148570 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE-CHALLENGED ANIMALS - Methods and compostions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglobulins purified from animal blood can modulate the immune system for treatment of respiratory disease challenges, as well as modulate serum IgG levels for treatment of immune dysfunction disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. | 2012-06-14 |
20120148571 | AMINO ACID SEQUENCES THAT BIND TO SERUM PROTEINS IN A MANNER THAT IS ESSENTIALLY INDEPENDENT OF THE PH, COMPOUNDS COMPRISING THE SAME, AND USES THEREOF - The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin essentially independently in the pH range of 5 to 8; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. | 2012-06-14 |
20120148572 | NOVEL ANTIBODIES - The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them. | 2012-06-14 |
20120148573 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF IMMUNE DISORDERS - The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. | 2012-06-14 |
20120148574 | Diagnostic Markers for Ankylosing Spondylitis - The present invention discloses methods and agents for diagnosing the presence or risk of development of ankylosing spondylitis (AS) in mammals, which are based on the detection of polymorphisms within any one or more of the ARTS-1 gene, the IL-23R gene, the TNFR1 gene locus, the TRADD gene locus, the IL-1R1 gene locus, the IL-1R2 gene locus, the CD74 gene locus and the chromosome loci 2P15, 2Q31.3 and 4Q13.1. The present invention also features methods for the treatment or prevention of AS based on the diagnostic methods. | 2012-06-14 |
20120148575 | Methods Of Reducing Eosinophil Levels - The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung. | 2012-06-14 |
20120148576 | HUMANIZED ANTI-CD 19 ANTIBODY FORMULATIONS - The present invention provides stable liquid formulations comprising chimeric and humanized versions of anti-CD 19 mouse monoclonal antibodies that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders. | 2012-06-14 |
20120148577 | USE OF HIGH-DOSE, POST-TRANSPLANTATION OXAZAPHOSPHORINE DRUGS FOR REDUCTION OF TRANSPLANT REJECTION - A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia. | 2012-06-14 |
20120148578 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2012-06-14 |
20120148579 | ANTIBODIES TO OX-2/CD200 AND USES THEREOF - This application provides methods and compositions for modulating and/or depleting CD200 positive cells. | 2012-06-14 |
20120148580 | METHODS FOR IDENTIFICATION OF SITES FOR IGG CONJUGATION - The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease. | 2012-06-14 |
20120148581 | USE OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES, SUCH AS TYPE 2 DIABETES - The present invention provides methods, compositions and kits for treating and detecting type 2 diabetes and/or conditions that may be regulated or normalised via inhibition of NKG2D, such as cardiovascular diseases. | 2012-06-14 |
20120148582 | ENGINEERED ANTI-IL-23R ANTIBODIES - Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2012-06-14 |
20120148583 | CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct intrathecal or direct epidural injection. | 2012-06-14 |
20120148584 | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE THREATMENT OF EARLY STAGE TUMORS - Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy. | 2012-06-14 |
20120148585 | FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES - The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies. | 2012-06-14 |
20120148586 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS - Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies. | 2012-06-14 |
20120148587 | POLYPEPTIDE FORMULATION - The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same. | 2012-06-14 |
20120148588 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 2012-06-14 |
20120148589 | HUMAN CANCER-RELATED GENE, ITS ENCODED PRODUCTS AND APPLICATIONS - The invention discloses a human cancer-related gene, LAPTM4B, its encoded products and their applications thereof. This human cancer-related gene provided by this invention comprises one of the following nucleotide sequences: (1) SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 6, or SEQ ID No: 8 in the sequence listings; (2) SEQ ID No: 4, SEQ ID No: 5, or SEQ ID No: 7 in the sequence listings which are proteins encoded by the polynucleotides in sequences of SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 and SEQ ID No: 6. (3) Applications of the polynucleotides and polypeptides in the listings in diagnosis and treatments of cancer. This invention enables the developments of new cancer diagnostic markers and new anti-cancer medicines. It would create a significant impact on human society. | 2012-06-14 |
20120148590 | CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY - The invention provides cell-permeable peptides that bind to JNK protein and inhibit JNK-mediated effects in JNK-expressing cells. | 2012-06-14 |
20120148591 | Antibodies That Bind Amyloid Oligomers - Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide. | 2012-06-14 |
20120148592 | NEUTRALIZING ANTI-CCL20 ANTIBODIES - The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer. | 2012-06-14 |
20120148593 | Neutralizing Antibodies And Methods Of Use Thereof - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies. | 2012-06-14 |
20120148594 | MIMOTOPES OF HIV AND USES THEREOF - The invention provides methods, compositions and kits for treating and or preventing diseases having immunological components associated with their etiology and/or progression (e.g., an HIV infection). A mimotope that mimics an epitope of an antigen may be administered to an individual to induce or enhance an immune response for the treatment of a disease. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to a mimotope may be administered to an individual to treat or prevent a disease. Antibodies directed to HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS). In another embodiment, the invention provides compositions and methods for isolating an epitope specific B cell. | 2012-06-14 |
20120148595 | GABA-LINKED ANTHRACYCLINE-LIPID CONJUGATES - The present invention relates to GABA-linked anthracycline-lipid conjugates and to methods of using the conjugates to treat cancer. Methods for making the GABA-linked anthracycline lipid conjugates are also provided. | 2012-06-14 |
20120148596 | MOLECULAR CONJUGATES COMPRISING HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS - Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2012-06-14 |
20120148597 | HUMAN MONOCLONAL ANTIBODIES TO CTLA-4 - In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein. | 2012-06-14 |
20120148598 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 2012-06-14 |
20120148599 | METHODS AND COMPOSITIONS FOR NEURAL DISEASE IMMUNOTHERAPY - The invention provides antibodies to specific neural proteins and methods of using the same. | 2012-06-14 |
20120148600 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2012-06-14 |
20120148601 | BACTERIAL SUPERANTIGEN VACCINES - The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described. | 2012-06-14 |
20120148602 | Cancer Treatment With Endothelin Receptor Antagonists - The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation. | 2012-06-14 |
20120148603 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (I): and tautomers thereof, and solvates, prodrugs, esters, and deuterates of said compounds and said tautomers, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R | 2012-06-14 |
20120148604 | TRP INHIBITORS AND USES THEREOF - The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function. | 2012-06-14 |
20120148605 | Immunomodulatory Methods And Systems For Treatment And/Or Prevention Of Atherosclerosis And Related Proteins, Peptide And Compositions - Immunostimulatory methods and systems for treating or preventing atherosclerosis and/or a condition associated thereto in an individual. | 2012-06-14 |
20120148606 | Neutralizing Antibodies And Methods Of Use Thereof - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies. | 2012-06-14 |
20120148607 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 2012-06-14 |
20120148608 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-06-14 |
20120148609 | INTRACORONARY DEVICE AND METHOD OF USE THEREOF - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 2012-06-14 |
20120148610 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-06-14 |
20120148611 | Cyclophosphamide in Combination with Anti-Idiotypic Vaccines - The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens. | 2012-06-14 |
20120148612 | GRASS PEPTIDES FOR VACCINE - The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 2012-06-14 |
20120148613 | MULTIVALENT ENTRAIN-AND-AMPLIFY IMMUNOTHERAPEUTICS FOR CARCINOMA - The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response. | 2012-06-14 |
20120148614 | Interaction of Moraxella Catarrhalis with Epithelial Cells, Extracellular Matrix Proteins and the Complement System - The present disclosure relates to surface proteins of | 2012-06-14 |
20120148615 | POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE - Polypeptides comprising non-typeable | 2012-06-14 |
20120148616 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2012-06-14 |
20120148617 | MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NBM1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870. | 2012-06-14 |
20120148618 | MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870. | 2012-06-14 |
20120148619 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 2012-06-14 |
20120148620 | COMPOSITIONS AND METHODS FOR VACCINATING CATTLE - The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against | 2012-06-14 |
20120148621 | METHODS AND COMPOSITIONS FOR PROMOTING A CELL-MEDIATED IMMUNE RESPONSE - The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from | 2012-06-14 |
20120148622 | Live Attenuated Influenza Virus Vaccines Comprising Microrna Response Elements - The invention is directed to novel live attenuated influenza virus (LAIV) vaccines comprising one or more microRNA (miRNA) Response Element(s) (MRE) within an influenza virus genome. The MREs useful for the present invention can be derived from any miRNA which is highly expressed in influenza-targeted cells of an animal in need of vaccination but are not expressed or are expressed at very low levels in species (e.g., embryonated chicken eggs) or cell lines used for a large-scale vaccine production. This allows efficient vaccine production but renders the vaccine virus susceptible to attenuation in the influenza-targeted cells of vaccinated animals expressing a cognate miRNA. | 2012-06-14 |
20120148623 | VACCINATION FOR LAWSONIA INTRACELLULARIS - The present invention include a method of protecting an animal against | 2012-06-14 |
20120148624 | MUTANTS OF CHOLESTEROL-DEPENDENT CYTOLYSINS AND USES THEREOF - Mutants of cholesterol-dependent cytolysins comprising at least one amino acid substitution in at least one of Loop 1, Loop 2, or Loop 3 of Domain 4, nucleic acids, vectors, and host cells encoding such polypeptide mutants, and compositions and vaccines comprising such polypeptide mutants. | 2012-06-14 |
20120148625 | Anti-bacterial Vaccine Compositions - Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines. | 2012-06-14 |
20120148626 | REDUCTION OF IN VITRO GENOTOXICITY OF POLLEN EXTRACTS BY REMOVAL OF FLAVONOIDS - The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts. | 2012-06-14 |
20120148627 | Compositions and Methods for Treatment of Neoplastic Disease - Herein we provide cDNA extracted from tumor cells, normal cells or treatment resistant tumor cells that have been transduced with virus capable of altering self and/or tumor associated antigens (VASTA) fused recombinantly to nucleic acids encoding wild type superantigens, superantigens, superantigen homologues and superantigen-tumor specific targeting molecules and further linked to a costimulatory molecule. The extracted cDNA is linked to a VASTA and delivered to tumor bearing hosts parenterally wherein they induce a tumoricidal response. These agents are also incorporated into a tumor tropic cell carrier for protected delivery to tumor. | 2012-06-14 |
20120148628 | Compositions and methods for treatment of cancer - The present invention contemplates therapeutic constructs comprising superantigen homologues devoid of neutralizing antibodies in human sera conjugated recombinantly to costimulatory and tumor targeting molecules for treatment of cancer | 2012-06-14 |
20120148629 | NUTRITIONAL COMPOSITION COMPRISING LACTOCOCCUS STRAINS AND REDUCING ALLERGY SYMPTOMS, ESPECIALLY IN INFANTS AND CHILDREN - A complete nutritional composition comprising | 2012-06-14 |
20120148630 | PREVENTION OF INFARCT EXPANSION - Provided are methods and kits for safe and effective therapy that can be administered early after a heart attack in order to prevent progressive heart dilatation and resultant loss of function. The therapy includes the administration of particulate compositions to a region comprising an infarct or a portion thereof. | 2012-06-14 |
20120148631 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes. | 2012-06-14 |
20120148632 | METHODS FOR COMPLEX TISSUE ENGINEERING - A simple, highly flexible and scalable platform for making functional complex tissues with heterogeneity and irregularity is provided. The method includes combining undifferentiated cells, such as pluripotent or multipotent stem cells, with a biomaterial to make multiple undifferentiated or naïve subunits, exposing the undifferentiated or naïve subunits to different cell culture environments for induction of differentiation towards different lineages as required by that complex tissue, and combining the then functional subunits with or without the undifferentiated subunits. The differentiated subunits thus combined can be cultured under biological, chemical, and/or physical culture conditions suitable to fine-tune the structural and functional properties of the bioengineered complex tissue to form a bioengineered tissue graft that mimics the structural and functional characteristics of native complex tissue. The bioengineered tissue graft can then used to replace dysfunctional tissue. | 2012-06-14 |
20120148633 | BINARY AND TERTIARY GALVANIC PARTICULATES AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials. | 2012-06-14 |
20120148634 | NOVEL FORMULATION OF NAPROXEN - The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments. | 2012-06-14 |
20120148635 | GALLIUM FORMULATION FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES - A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as | 2012-06-14 |
20120148636 | MICROPARTICLES AND METHOD OF MAKING MICROPARTICLES - A process for producing micronized dispersed micro-particles and to micro-particles produced by this process. | 2012-06-14 |
20120148637 | NANOPARTICULATE OLMESARTAN MEDOXOMIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. | 2012-06-14 |
20120148638 | Steroid Solavates - A dpi formulation comprises a solvate of beclomethasone with a non-cyclic, straight or branched C | 2012-06-14 |
20120148639 | SUBSTRATE FOR FEEDING CELLS AND/OR TISSUES, CELL/TISSUE-FEEDER AND METHOD FOR THE PRODUCTION OF THE SAME, METHOD FOR THE REGENERATION OF TISSUES, AND METHOD FOR THE PRODUCTION OF POROUS BODIES - A substrate for feeding cells and/or tissues which is composed of a porous body having a thin film surface and a porous surface and which can be used in the regenerative medical techniques. A cell/tissue feeder is produced by cultivating tissues on the porous surface of the porous body. Cells are seeded on the porous surface of the body, followed by the cultivation of the cells to thus form and/or regenerate tissues. An aqueous solution of silk proteins, to which a water-soluble organic solvent is added, is introduced into a mold whose bottom or top surface is surface-roughened, followed by freezing the aqueous solution and then thawing the frozen aqueous solution to form a porous body having a thin film surface and a porous surface. | 2012-06-14 |
20120148640 | Pharmaceutical Composition Comprising Pimobendan - The invention relates to novel solid formulations comprising as pharmaceutically active compound pimobendan and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, wherein the solid formulations according to the invention are used. | 2012-06-14 |
20120148641 | METHODS OF TREATMENT OF ENDOBRONCHIAL INFECTIONS - The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days. | 2012-06-14 |
20120148642 | MULTI-DOMAIN AMPHIPATHIC HELICAL PEPTIDES AND METHODS OF THEIR USE - Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein. | 2012-06-14 |
20120148643 | TOOTH BLEACHING CATALYTIC AND APPLICATION THEREOF - A tooth bleaching catalytic, the manufacturing method and the applications thereof are provided, wherein the tooth bleaching catalytic comprises a plurality of mesoporous silica nano-particles (MSNs), and the MSNs at least comprise a condensate having histidine, silane and a plurality of metal ions. | 2012-06-14 |
20120148644 | Encapsulated Active Materials - The invention relates to microcapsule composition which encapsulates active material that may be used in products for washing and cleaning and/or care and protection of animate or inanimate. The invention also relates to polyurethane and polyurea microcapsules that may be modified with additional polymers. | 2012-06-14 |